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Induction of cell cycle arrest via the p21, p27–cyclin E,A/Cdk2 
pathway in SMMC-7721 hepatoma cells by clioquinol
Clioquinol has been shown to have anticancer activity in 
several carcinoma cells. In this study, we preliminarily ex-
amined the effect of clioquinol in human SMMC-7721 hepa-
toma and QSG-7701 normal hepatic cells. Our results indi-
cated that clioquinol did not significantly affect survival of 
QSG-7701 cells, whereas it reduced cell viability in a con-
centration- and time-dependent manner in SMMC-7721 
cells. Clioquinol did not trigger autophagy and apoptosis, 
while it induced cell cycle arrest in the S-phase in SMMC-
7721 cells. Additionally, down-regulation of cyclin D1, A2, 
E1, Cdk2 and up-regulation of p21, p27 were detected after 
the treatment with clioquinol. The results demonstrated for 
the first time that clioquinol suppressed cell cycle progres-
sion in the S-phase in SMMC-7721 cells via the p21, p27–cy-
clin E,A/Cdk2 pathway. This suggests that clioquinol may 
have a therapeutic potential as an anticancer drug for cer-
tain malignances.
Keywords: clioquinol, human SMMC-7721 hepatoma cells, 
cell cycle S-phase arrest, cyclin E/A-Cdk2
Clioquinol (5-chloro-7-iodoquinolin-8-ol), a quinoline compound, acts as a mild met-
al chelator and/or ionophore, binding metals like copper and zinc. It has been used as an 
antibacterial drug for treating diarrhea and skin infections (1). However, clioquinol was 
withdrawn from the market due to subacute myelo-optic neuropathy (SMON) in Japan (2, 
3). In recent years, toxicology studies of clioquinol performed in both animals and humans 
show it has low side effects (4, 5). Owing to its ability to bind copper/zinc and dissolve 
beta-amyloid plaques by activating autophagy in the brain, clioquinol has re-emerged as 
a potential therapy for Alzheimer’s disease (6, 7). Clioquinol was also reported to have 
anticancer activity in several carcinoma cells (8–11). Especially, in preclinical models of 
hematologic malignancies and solid tumors, clioquinol displays anticancer efficacy in vitro 
and in vivo (12–14). Thus, clioquinol may be a novel anti-cancer agent. However, pharma-
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Clioquinol was obtained from Tokyo KaSei Industry Co., Ltd. (Japan) and dissolved 
in DMSO. Cell counting kit-8 was purchased from Dojindo molecular technologies Inc. 
(Dojindo, Japan). Propidium iodine (PI), Hoechst 33258 and Acridine Orange (AO) were 
purchased from Sigma-Aldrich (uSA). Annexin V-fITC apoptosis detection kit was pur-
chased from (Molecular Biology & Chemistry, China). ECL western blotting detection re-
agents were purchased from GE Healthcare (uK). Other reagents used in the study were 
purchased from Sinopharm Chemical Reagent Co., Ltd. (China).
P21, P27, cyclin A, cyclin E and Cdk2 rabbit monoclonal antibodies were purchased 
from Epitomics Inc. (uSA). HRP-conjugated monoclonal mouse anti-glyceraldehyde- 
-3-phosphate dehydrogease (GAPDH) was purchased from Kangchen Biotech (China). The 
secondary antibody HRP-labeled goat anti-rabbit IgG (H+L) was purchased from Novopro-
tein Scientific Inc. (China).
Cell line and cell culture
Human hepatoma cell line SMMC-7721 and immortal hepatocytes QSG-7701 were 
supplied by the Type Culture Collection of the Chinese Academy of Sciences (China). Cells 
were cultured at 37 °C under a humidified 5 % CO2 atmosphere in DMEM and RPMI-1640 
medium supplemented with 10 % fetal bovine serum (fBS) (GIBCO, uSA) and 1 % penicil-
lin-streptomycin (10,000 u mL–1 penicillin and 10 mg mL–1 streptomycin (Solarbio Life 
Science, China).
Cell viability and apoptosis assay
Cell viability was evaluated by Cell counting kit-8 according to the manufacturer’s 
instructions. Cells were plated in 96-well micro-well plates in 0.1 mL medium, at a density 
of 1 × 105 cells per well. The cells were incubated without clioquinol (0.1 % DMSO) or with 
1, 2, 5 mmol L–1 clioquinol solution. Absorbance was measured at 450 nm with a Genios 
multifunction-reader (Tecan GENios Pro, Tecan Group Ltd., Switzerland). Apoptosis was 
examined using flow cytometry (fACScalibur, BD Bioscenices, uSA) after staining the cells 
with annexin V-fITC and propidium iodide (PI) (Majorbio Bio-Pharm Technology Co., China). 
Data analy sis was performed with standard CellQuest software (BD fACScanTM,  uSA).
Staining
Hoechst 33258 staining. – SMMC-7721 cells at 2 × 105 cells mL–1 were seeded in 24-well 
plates and treated with 5 mmol L–1 clioquinol or 0.1 % DMSO for 72 h. The cells were fixed 
in 4 % paraformaldehyde at 4 °C for 30 min, and then stained with 5 μg mL–1 Hoechst 
33258, a DNA-specific fluorescent dye, for 10 min at 37 °C. The stained cells were observed 
under a fluorescence microscope (Olympus BX51, Japan).
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Vital cell staining with acridine orange for autophagy detection. – Cells were seeded on 
slides and staining with acridine orange was performed according to published proce-
dures (15), adding a final concentration of 1 μg mL–1 acridine orange for 30 min at 37 °C. 
Photographs were obtained with a fluorescence microscope (200×) (Olympus BX51).
Cell cycle analysis
Cellular DNA content was determined by flow cytometry. After incubation with 5 
mmol L–1 or 0.1 % DMSO for 48 and 72 h, cells were harvested, washed twice with ice-cold 
PBS, fixed with 70 % ethanol for 18 h at 4 °C. Cells were then washed twice with ice-cold 
PBS and re-suspended in PBS. RNA was digested with RNase A (10 μg mL–1) and DNA was 
stained with PI (10 μg mL–1). Stained cells were analyzed with a fACScan flow cytometer 
(Becton Dickinson, uSA). Cell cycle distribution was analyzed by measuring cell fractions 
in G0/G1, S, and G2/M phases using Modfit LT 2.0 software (Verity Software, Topsham, 
uSA). Results shown are representative of three independent experiments.
Real-time PCR
The cells were incubated with 5 mmol L–1 clioquinol or 0.1 % DMSO for 72 h. Total RNA 
extraction and complementary DNA (cDNA) preparation were performed using TRNzol 
reagent and fastQuant RT kit (with gDNase, Tiangen, China), respectively. The real-time 
PCR analysis was performed in triplicate using SuperReal PreMix Plus (SYBR Green) 
(Tiangen, China) in a CfX96 Real-Time PCR Detection System (Bio-Rad, uSA). The 
reactions were as follows: activation of the Taq DNA polymerase at 95 °C for 15 min and 
40 cycles of 95 °C for 10 s and 60 °C for 32 s. The primers are listed in Table I. Gapdh was 
selected as internal control. The relative changes in gene expression were calculated using 
the equation by Livak (16):
 2 –ΔΔCT, where ΔΔCT = (CT,Target – CT,Gapdh)Treatment – (CT,Target – CT,Gapdh)Control
CT,Target is the threshold cycle for internal reference Gapdh gene. The treatment and control 
mean the cells treated with and without clioquinol, respectively. Data were expressed as a 
fold change compared to control samples (mean ± SD of three replicates).
Table I. Primer sequences used in real-time PCR analysis
Gene name Left primer Right primer
Cyclin A2 TGGAAAGCAAACAGTAAACAGCC GGGCATCTTCACGCTCTATTT
Cyclin D1 CCGTCCATGCGGAAGATC ATGGCCAGCGGGAAGAC






Z. Huang et al.: Induction of cell cycle arrest via the p21, p27–cyclin E,A/Cdk2 pathway in SMMC-7721 hepatoma cells by clioquinol, 
Acta Pharm. 65 (2015) 463–471.
 
Western blot
The cells were incubated with 5 mmol L–1 clioquinol or 0.1 % DMSO for 72 h. Cell ly-
sates were obtained using standard techniques and RIPA lysis buffer (Beyotime Institute 
of Biotechnology, China). Protein concentration was determined by the Bradford protein 
assay (Bio-Rad, uSA). A quantity of 50 μg total protein per lane was separated by 12 % 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
to Amersham Hybond-P polyvinylidene fluoride (PVDf) membranes (GE Healthcare). 
Membranes were blocked with 5 % milk powder in 0.05 % Tween-Tris buffer saline (TBS), 
incubated with specific primary antibodies and then with the appropriate horseradish 
peroxidase-conjugated secondary antibodies (Sinbio, China). GAPDH was used as an in-
ternal standard. Detection of the target proteins on the membranes was performed using 
the ECL western blotting detection reagents (GE Healthcare, uK). Signal density was de-
tected using the Mf-ChemiBIS family including gel capture software (DNR Bio-Image 
system, Ltd., Israel) and quantitatively analyzed by densitometry using the Image J soft-
ware.
Statistical analysis
The experiments were repeated three times. The data are presented as the mean ± SD 
(for each group). Statistical analysis was performed using Student’s t-test (paired). Values 
of p < 0.05 were considered to be statistically significant.
RESuLTS AND DISCuSSION
Clioquinol causes SMMC-7721 cell death
using the wST-8 based colorimetric assay cell counting kit 8, the effects of clioquinol 
on cell viability were measured. As shown in Fig. 1a, clioquinol induced a time- and 
concentration-dependent decrease in the viability of SMMC-7721 cells. After 72 hours of 
treatment, the half maximal inhibitory concentration (IC50) of clioquinol was 1.0 mmol L–1. 
It is noteworthy that clioquinol did not induce significant decrease in the viability of 
normal human liver cells QSG-7701 (fig. 1b). Obviously, the cell growth inhibitory effect 
of clioquinol on the human hepatoma SMMC-7721cells was stronger than that on the 
normal liver QSG-7701cells. In addition, the highest concentration of clioquinol (5 mmol 
L–1) in our study did not exhibit significant cytotoxicity in QSG-7701 cells. The results 
further confirmed that clioquinol has low side effects (8–11).
Clioquinol does not induce cell apoptosis and autophagy
we sought to explore the possible inhibition of SMMC-7721 cell growth. Annexin 
V-fITC and PI staining assay were used to detect cell apoptosis. No significant induction 
of apoptosis occurred in SMMC-7721 cells after 48-h treatment with 5 mmol L–1 clioquinol 
(data not shown). Then, Hoechst 33258, a DNA-specific fluorescent dye, was chosen to 
observe the morphologic characteristics of apoptosis in SMMC-7721 cells. As shown in fig. 
2, no apoptotic cells could be found after the clioquinol treatment for 72 h by fluorescence 
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microscopy. The above observations indicate that apoptosis is not the cause of cell death 
induced by clioquinol. we then questioned if it induced autophagy, another form of cell 
death, in SMMC-7721 cells. To address this issue, vital staining of cells treated with 
clioquinol for 72 h was performed with acridine orange, a selective fluorescent marker of 
autophagic vesicles. As shown in Figure 2, no acidic vesicles were observed. Likewise, 
clioquinol did not induce autophagy in SMMC-7721 cells.
Cell cycle arrest is induced by clioquinol
To examine whether clioquinol-induced growth inhibition was associated with cell 
cycle regulation, the cell cycle distribution was analyzed by flow cytometry. After SMMC-
7721 cells were incubated with clioquinol for 48 and 72 h, cells were harvested and further 
prepared for cell cycle analysis. figs. 3a and b showed that clioquinol treatments for 48 and 
72 h resulted in accumulation of SMMC-7721 cells in the S phase. Cell populations in the 
fig. 1. The inhibitory effect of clioquinol on the: a) viability of SMMC-7721 cells and b) QSG-7701 cells.
fig. 2. Analysis of apoptosis and autophagy after clioquinol treatment in SMMC-7721 cells.
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S phase were 35.2 % and 36.6 % in control SMMC-7721 cells. However, after 48 and 72 h of 
incubation with 5 mmol L–1 clioquinol, the S population was noticeably enhanced by 44.8 
and 58.2 %, respectively (p < 0.05) (Fig. 3).
fig. 3. Clioquinol inhibits cell cycle progression and causes S-phase arrest in SMMC-7721 cells.
Changes of cell cycle related genes mRNA and proteins expression
In order to determine whether clioquinol was able to regulate cell cycle related gene 
expression, a real-time PCR experiment was performed in the cell extracts prepared from 
SMMC-7721 cells. The results showed that clioquinol reduced the levels of cyclin A2, cyclin 
D1, cyclin E1 and Cdk2 (p < 0.05), and increased the levels of p21 and p27 72 h after treat-
ment (p < 0.01) (fig. 4). Next, western blot with specific antibodies was done to detect the 
changes of the related protein expression levels. we observed a reduction of cyclin A2, 
cyclin D1, cyclin E1 and Cdk2 and an increase of p21 and p27 after the treatment with 
clioquinol for 72 h (fig. 5). Therefore, clioquinol regulates mRNA and subsequent protein 
levels of certain cell cycle-related genes to induce the S-phase cell cycle arrest in SMMC-
7721 cells.
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Clioquinol has been shown to have anticancer activity in several experimental model 
systems via several different mechanisms of action. for instance, it generates free zinc in 
lysosomes as a zinc ionophore (17), inhibits Nf-kappa B activity (12, 17, 18), or proteasome 
activity (8, 9, 19), induces the cytoplasmic clearance of X-linked inhibitor of apoptosis pro-
tein (20), or induces DNA double-strand break and subsequent activation of ATM/p53 
signaling (21). The present study firstly demonstrated that clioquinol induced cell-cycle 
arrest in the S phase in SMMC-7721 hepatoma cells. furthermore, according to the current 
data, the S phase arrest in clioquinol treated SMMC-7721 cells was accompanied by the 
alteration of various cell cycle-related proteins. SMMC-7721 cells treated with clioquinol 
showed down-regulation of cyclin A2, cyclin D1, cyclin E1 and Cdk2, and up-regulation 
of p21 and p27. A previous study has reported that the S phase cell-cycle arrest occurs with 
the loss of Cdk2 activity due to up-regulation of p21 and reduced formation of active com-
plex cyclin E/Cdk2 kinase (22). Yeo et al. (23) suggested that an intra-S-phase checkpoint 
occurs via phosphorylation of Chk1/2, which leads to degradation of cdc25A and deactiva-
tion of cyclin E/A-Cdk2 complex. In this study, up-regulation of p21, p27 and down-regu-
fig. 4. Assessment of the relative mRNA level of cell cycle related genes after clioquinol treatment in 
SMMC-7721 cells by real-time PCR.
fig. 5. western blotting analysis of the expression level of cell cycle related proteins after clioquinol 
treatment in SMMC-7721 cells.
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lation of cyclin E1, cyclin A2 and Cdk2 are considered to be involved in the S-phase arrest 
induced by clioquinol in SMMC-7721 cells. In addition, clioquinol regulates the mRNA 
levels of these cell cycle-related genes and results in subsequent protein levels to induce 
the S-phase cell cycle arrest in SMMC-7721 cells. However, the cell cycle regulation by 
clioquinol needs to be elucidated further.
CONCLuSIONS
Our preliminary findings demonstrate for the first time that clioquinol exerts its cell 
death effects via S-phase cell-cycle arrest in SMMC-7721 hepatoma cells. Additionally, the 
growth inhibitory effect after exposure to clioquinol is not caused by apoptosis and/or 
autophagy in SMMC-7721 cells. Although clioquinol exhibits different modes of action in 
different types of cancer cells, here it suppresses cell cycle progression in the S-phase in 
SMMC-7721 cells via the p21, p27–cyclin E,A/Cdk2 pathway. Our results strongly suggest 
that clioquinol should be additionally investigated as a potential novel chemotherapeutic 
agent for the treatment of some malignant human cancers.
Acknowledgements. – we are grateful to Dr. Deeksha Vishwamitra for her kind assistance in lan-
guage correction. This work was sponsored by grants from the Natural Science foundation of Shang-
hai (15ZR1400200), Shanghai Scientific and Technological Innovation Project (14520720700), State 
Education Ministry and fundamental Research funds for the Central universities (2232014A3-03, 
2232015G1-41 and 222201313010), the Applied Basic Research Project of Promotion Plan for Scientific 
and Technological Innovation in Qinghai Province (2015-ZJ-703).
REfERENCES
  1.  L. Cahoon, The curious case of clioquinol, Nat. Med. 15 (2009) 356–359; DOI: 10.1038/nm0409-356.
  2.  J. Tateishi, Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals, 
Neuropathology 20 (2000) S20–S24; DOI: 10.1046/j.1440-1789.2000.00296.x.
  3.  T. Tsubaki, Y. Honma and M. Hoshi, Neurological syndrome associated with clioquinol, Lancet 1 
(1971) 696–697.
  4.  L. Helmuth, Neuroscience. An antibiotic to treat Alzheimer’s? Science 290 (2000) 1273–1274; DOI: 
10.1126/science.290.5495.1273a.
  5.  X. Mao and A. D. Schimmer, The toxicology of clioquinol, Toxicol. Lett. 182 (2008) 1–6; DOI: 
10.1016/j.toxlet.2008.08.015.
  6.  M. H. Park, S. J. Lee, H. R. Byun, Y. Kim, Y. J. Oh, J. Y. Koh and J. J. Hwang, Clioquinol induces 
autophagy in cultured astrocytes and neurons by acting as a zinc ionophore, Neurobiol. Dis. 42 
(2011) 242–251; DOI: 10.1016/j.nbd.2011.01.009.
  7.  S. R. Bareggi and u. Cornelli, Clioquinol: review of its mechanisms of action and clinical uses in 
neurodegenerative disorders, CNS Neurosci. Ther. 18 (2012) 41–46; DOI: 10.1111/j.1755-5949.2010. 
00231.x.
  8.  K. G. Daniel, D. Chen, S. Orlu, Q. C. Cui, f. R. Miller and Q. P. Dou, Clioquinol and pyrrolidine 
dithiocarbamate complex with copper to form proteosome inhibitors and apoptosis inducers in 
human breast cancer cells, Breast Cancer Res. 7 (2005) 897–908; DOI: 10.1186/bcr1322.
  9.  T. Du, G. filiz, A. Caragounis, P. J. Crouch and A. R. white, Clioquinol promotes cancer cell 
toxicity through tumor necrosis factor alpha release from macrophages, J. Pharmacol. Exp. Ther. 
324 (2008) 360–367; DOI: 10.1124/jpet.107.130377.
471
Z. Huang et al.: Induction of cell cycle arrest via the p21, p27–cyclin E,A/Cdk2 pathway in SMMC-7721 hepatoma cells by clioquinol, 
Acta Pharm. 65 (2015) 463–471.
 
10.  M. w. Lee, P. C. Lin and w. C. Tsai, The anti-cancer effects of clioquinol on oral cancer, EACR-23 
Poster Sessions/Eur. J. Cancer 50 (2014) S42.
11.  O. Afzal, S. Kumar, M. R. Haider, M. R. Ali, R. Kumar, M. Jaggi and S. Baw, A review on anticancer 
potential of bioactive heterocycle quinolone, Eur. J. Med. Chem. 97 (2015) 871–910; DOI: 10.1016/j.
ejmech.2014.07.044.
12.  w. Q. Ding, B. Liu, J. L. Vaught, H. Yamauchi and S. E. Lind, Anti-cancer activity of the antibiotic 
clioquinol, Cancer Res. 65 (2005) 3389–3395; DOI: 10.1158/0008-5472.CAN-04 -3577.
13.  X. Mao, X. Li, R. Sprangers, X. wang, A. Venugopal, T. wood, Y. Zhang, D. A. Kuntz, E. Coe, S. 
Trudel, D. Rose, R. A. Batey, L. E. Kay and A. D. Schimmer, Clioquinol inhibits the proteasome 
and displays preclinical activity in leukemia and myeloma, Leukemia 23 (2009) 585–590; DOI: 
10.1038/leu.2008.232.
14.  A. D. Schimmer, Y. Jitkova, M. Gronda, Z. wang, J. Brandwein, C. Chen, V. Gupta, A. Schuh, K. 
Yee, J. Chen, S. Ackloo, T. Booth, S. Keays and M. D. Minden, A Phase I study of the metal iono-
phore clioquinol in patients with advanced hematologic malignancies, Clin. Lymphoma Myeloma 
Leuk. 12 (2012) 330–336; DOI: 10.1016/j.clml.2012.05.005.
15.  T. Kanzawa, Y. Kondo, H. Ito, S. Kondo and I. Germano, Induction of autophagic cell death in 
malignant glioma cells by arsenic trioxide, Cancer Res. 63 (2003) 2103–2108.
16.  K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using real-time 
quantitative PCR and the 2-delta delta CT method, Methods 52 (2001) 402–408; DOI: 10.1006/
meth.2001.1262.
17.  H. Yu, Y. Zhou, S. E. Lind and w. Q. Ding, Clioquinol targets zinc to lysosomes in human cancer 
cells, Biochem. J. 417 (2009) 133–139; DOI: 10.1042/BJ20081421.
18.  H. Yu, J. R. Lou and w. Q. Ding, Clioquinol independently targets Nf kappa B and lysosome 
pathways in human cancer cells, Anticancer Res. 30 (2010) 2087–2092.
19.  D. Chen, Q. C. Cui, H. Yang, R. A. Barrea, f. H. Sarkar, S. Sheng, B. Yan, G. P. Reddy and Q. P. Dou, 
Clioquinol, a therapeutic agent for Alzheimer’s disease, has proteasome-inhibitory, androgen 
receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer 
cells and xenografts, Cancer Res. 67 (2007) 1636–1644; DOI: 10.1158/0008-5472. CAN -06-3546.
20.  M. A. Cater and Y. Haupt, Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of 
apoptosis protein (XIAP): therapeutic indication for prostate cancer, Biochem. J. 436 (2011) 481–491; 
DOI: 10.1042/BJ20110123.
21.  M. Katsuyama, K. Iwata, M. Ibi, K. Matsunob, M. Matsumotob and C. Yabe-Nishimura, Clioquinol 
induces DNA double-strand breaks, activation of ATM, and subsequent activation of p53 signal-
ing, Toxicology 299 (2012) 55–59; DOI: 10.1016/j.tox.2012.05.013.
22.  C. Laezza, S. Pisanti, E. Crescenzi and M. Bifulco, Anandamide inhibits Cdk2 and activates Chk1 
leading to cell cycle arrest in human breast cancer cells, FEBS Lett. 580 (2006) 6076–6082; 
DOI:10.1016/j.febslet.2006.09.074.
23.  E. J. Yeo, J. H. Ryu, Y. S. Chun, Y. S. Cho, I. J. Jang, H. Cho, J. Kim, M. S. Kim and J. w. Park, YC-1 
induces S cell cycle arrest and apoptosis by activating checkpoint kinases, Cancer Res. 66 (2006) 
6345–6352; DOI: 10.1158/0008-5472.CAN-05-4460.
